In the context of PNH, for which pegcetacoplan has been approved, inhibition at the C3 level may confer benefits over C5 inhibition since the impaired opsonization should also prevent potential extravascular hemolysis by immune cell recognition and breakthrough hemolysis caused by ongoing formation of C5 convertases. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.